July 14, 2026

Looking Ahead to the Rocky Mountain Conference on Magnetic Resonance 2026

It’s that time of year again, with less than a month until the Rocky Mountain Conference on Magnetic Resonance, one of the premier magnetic resonance conferences in North America. Rocky Mountain is one of my favorite conferences of the year, being able to catch up with the science and the EPR community that helped build my scientific career. It’s always a week of great presentations and great conversations, and I’m excited to return once again to both learn about the latest developments, as well as share some of our own.

Structural biology retains an important place among the EPR community and the Rocky Mountain Conference. Biological applications are well represented, and as the structural biology industry continues to increase the emphasis on capturing biomolecular dynamics along with their existing structural characterizations, EPR is poised to provide that extra dimension of information. As I’ve mentioned in previous posts, structural biology, and related industries like drug discovery, is progressively moving from "what does it look like?" to "how does it move?”. Conferences like Rocky Mountain provide the tools to answer those questions.

During the conference, I'll be presenting a project I’ve worked on with a major industry partner using High Q’s fully automated FATHOM EPR system. This project involved difficult target proteins at low concentrations, and over the past few months we've been focusing on improving the automation, sensitivity, and phase stability over long acquisitions. We’ve been quietly and diligently working to make FATHOM into an instrument that is more dependable, day after day. For anyone working with biological samples, sensitivity is always valuable because the signals can be weak, and the sample is often limited. High phase stability allows for longer coherent averaging without worrying about drifts, retuning, or recalibrating. And in scenarios where material is difficult to prepare (for instance, notoriously challenging membrane proteins), being able to work with smaller sample volumes is vital.  

Every Rocky Mountain Conference seems to produce a few ideas nobody quite expected, a handful of new collaborations, and at least one conversation that ends up being far more important than it first appeared. If you're attending the Rocky Mountain Conference on Magnetic Resonance, I'd be happy to show you some of our recent work on the FATHOM, hear about the systems you're working on, and compare notes on where EPR is headed next.

See you in Utah!

‍

Our News

Related posts

Explore Insights
How to Validate Protein Dimerization Using DEER EPR, AUC, and SEC-MALS
How to Validate Protein Dimerization Using Electron Paramagnetic Resonance

Protein dimerization is one of the most widespread and functionally important forms of protein–protein interaction. Proteins rarely act in isolation in a biological environment; instead, they associate as homodimers, heterodimers or higher-order oligomers to form functional assemblies. This self-assembly occurs in every cellular compartment, from membranes to the nucleus and cytosol, and regulates processes ranging from enzymatic activation and signal transduction to pathogenic pathways. A dimer observed in a crystal structure, however, may represent either a genuine biological assembly or a contact created by crystal packing. A crystal structure provides detailed information about molecular architecture, but it does not by itself establish whether two molecules associate under relevant solution conditions, how strong that interaction is, or whether the subunits retain the same arrangement outside the lattice. Distinguishing between these possibilities is therefore an important task in structural biology, biophysics and pharmaceutical research, where protein–protein interactions can influence function, stability and the binding of potential drug candidates.

Read article
How to Validate Protein Dimerization Using Electron Paramagnetic Resonance
Protein Dimerization: Is your crystal structure dimer real? Testing protein dimers in solution
Protein Dimerization: Is your crystal structure dimer real?

Protein dimerization occurs when two protein molecules associate to form a dimer. A crystal structure can reveal how two protein molecules fit together, identifying an interface that may influence protein function or drug discovery. However, a dimer observed in a crystal does not necessarily represent the dominant assembly in solution. Crystal packing can stabilize contacts that are weak, transient, or absent under physiologically relevant conditions. For pharmaceutical researchers, this distinction matters because a proposed dimer interface may form a binding site, regulate protein activity, or provide a target for small molecules. Before using the structure to guide drug design, researchers need to establish whether the protein associates in solution and whether the arrangement of its subunits is consistent with the proposed model.

Read article
Protein Dimerization: Is your crystal structure dimer real?
AlphaFold-and-EPR-Spectroscopy: Partners to Understand Protein Structure, Dynamics and Function
AlphaFold and EPR Spectroscopy: Complementary Tools for Understanding Protein Structure, Dynamics and Function

Few tools have changed structural biology as quickly as AlphaFold2. Within a few years of its release, AlphaFold2 had become an important starting point for structural studies of many proteins. However, transporters, receptors, channels and many enzymes function through conformational changes, and ligand binding can shift proteins between different structural states. A single predicted model, however confident, represents one structural state rather than the full range of conformations a protein may populate. This is where Electron Paramagnetic Resonance (EPR) spectroscopy comes in.

Read article
AlphaFold and EPR Spectroscopy: Complementary Tools for Understanding Protein Structure, Dynamics and Function